The report contains two sections. The first analyses the incentive mechanisms in agricultural biotechnologies; it begins with a theoretical and historical analysis. The co-evolution of scientific paradigms and IPR in agricultural biotechnologies is then studied – in particular, the coexistence...

The New Zealand Biotechnology sector is worthy of study for several reasons. While there is a large and growing international literature on economic aspects of biotechnology innovation these studies concentrate on the United States and Europe. The New Zealand biotechnology sector may be expected...

The impact of patent protection on biomedical innovation has been a controversial issue. Although a "medical anti-commons" has been predicted due to a proliferation of patents on upstream technologies, evidence to test these concerns is only now emerging. However, most industrial surveys that...

The year 2005 marks the end of transition period for many developing countries with competent pharmaceutical sectors that competed in supplying generic versions of patented drugs to LDCs before, thereby inducing price competition and enhancing access to medicines. In a post-2005 scenario, the...

This article discusses the three concepts of `learning', `entrepreneurship' and `dynamics of the firm' in order to bridge some of the gap between micro and macro levels of analysis in evolutionary economics. This article addresses the following four issues: 1) Localized learning dependent on the...

We analyze policy options during an international health emergency to provide consumers in least developed countries access to patented life-extending pharmaceuticals. We show that a properly specified tariff against reexports achieves optimal price dispersion and is shown to depend on the...

We analyze policy options during an international health emergency to provide consumers in least developed countries access to patented life-extending pharmaceuticals. We show that a properly specified tariff against re?xports achieves optimal price dispersion and is shown to depend on the...

The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US. Over the last two decades, the industry has experienced some important...

This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over the world during the 1990s. This enabled us to characterise several features of the innovation process in pharmaceuticals, particularly the different role and comparative R&D performance of the...